BMJ  2006;332:1489 (24 June), doi:10.1136/bmj.332.7556.1489

Clinical review

Antiretroviral treatment of HIV infected adults

¹ University of California, San Francisco and San Francisco General Hospital, San Francisco, CA 94110, USA

The first 150 words of the full text of this article appear below.

Introduction

It has been about 10 years since the first report that three drug combination antiretroviral therapy can durably suppress HIV replication.¹ Subsequent studies have confirmed that when used appropriately highly active antiretroviral therapy (see box 1) can suppress viral replication to such low levels that the virus is unable to generate drug resistance mutations. Theoretically, once this level of viral suppression is achieved, treatment should work indefinitely, and the long term risk of morbidity and morality related to HIV associated immunodeficiency becomes negligible. Experience to date suggests that lifelong suppression of HIV is feasible.

This review is aimed at informing clinicians about the current management of HIV infection. Authoritative and continuously updated reviews are available on the web (for example, the US Department of Health and Human Services treatment guidelines at www.hivatis.org); this review does not attempt to exhaustively summarise the literature or to provide guidance to clinicians with . . . [Full text of this article]

Sources and selection criteria

What is the goal of therapy?

When to start therapy

What to start

When to switch therapy

Management of virological failure

Management of drug resistant HIV

When to stop

Risk of resistance during interruption of treatment and how to stop drugs

How to manage drug toxicities and other adverse events

How to manage drug toxicities and other adverse events

Nucleoside analogue associated lactic acidosis

How to manage drug-drug interactions

Global perspectives

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Human health resources are key to HIV treatment in Africa

Ntambwe Malangu
BMJ 2006 333: 98. [Extract] [Full Text]

Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study

UK Group on Transmitted HIV Drug Resistance
BMJ 2005 331: 1368. [Abstract] [Full Text] [PDF]

Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study

Caroline A Sabin, Teresa Hill, Fiona Lampe, Ryanne Matthias, Sanjay Bhagani, Richard Gilson, Mike S Youle, Margaret A Johnson, Martin Fisher, George Scullard, Philippa Easterbrook, Brian Gazzard, Andrew N Phillips on behalf of the steering committee of the UK Collaborative HIV Cohort Study Group
BMJ 2005 330: 695. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Hoffmann, D., Seebach, J., Cosma, A., Goebel, F. D., Strimmer, K., Schatzl, H. M., Erfle, V. (2008). Therapeutic vaccination reduces HIV sequence variability. FASEB J. 22: 437-444 [Abstract] [Full text]  
• Roberson, E. D., Mucke, L. (2006). 100 Years and Counting: Prospects for Defeating Alzheimer's Disease. Science 314: 781-784 [Abstract] [Full text]  
• Malangu, N. (2006). Human health resources are key to HIV treatment in Africa. BMJ 333: 98-98 [Full text]  

Rapid Responses:

Read all Rapid Responses

Freudian Slip

Brian McKinstry
bmj.com, 24 Jun 2006 [Full text]

The key global perspective on antiretroviral treatment in Africa is human resources for health

Ntambwe Malangu
bmj.com, 26 Jun 2006 [Full text]

New NIH study supports immune therapy treatment model

Gary J Minter
bmj.com, 28 Jun 2006 [Full text]

Online poll

Find out more >>